Berenberg analyst Shanshan Xu initiated Merus (MRUS) with a Buy and $35 price target telling investors it is an early Regernon (RGEN) with a well rounded platform, pursing novel target combos. Xu said Merus’ Biclonic platform is well positioned to yield many product candidates and believes its most advanced drug, MCLA-128, has a complementary mechanism of action to existing therapies and could potentially be used in different types of beast cancer treatments.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.